Novo Nordisk Pharmatech has announced it will be attending this year’s European Antibody Congress, which will be held in Congress Center Basel in Switzerland.

Running from 31 October to 2 November, the congress brings together a selection of industry professionals across the whole value chain to share unique insights.

The congress is co-located with the World Biosimilar Congress, World Immunotherapy Congress, and HPAPI World Congress, so attendance will have access to plenty of content across the three days and networking opportunities with more than 500 leading industry professionals.

Novo Nordisk Pharmatech invites you to visit booth #53 to discover more about recombinant insulin for innovative biologics and pharmaceutical-grade Quaternary ammonium compounds.

Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. A key component in serum-free growth media for mammalian cells, The company’s recombinant insulin is approved by regulatory bodies worldwide, including the Food and Drinks Administration (FDA) and European Medicines Agency (EMA). Its products are manufactured to current good manufacturing practice (cGMP) standards and it guarantees:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

Novo Nordisk Pharmatech delivers a proven record of product purity, reliability, and consistency with custom quality products for future therapies.